A meeting of the U.S. FDA's Antimicrobial Drugs Advisory Committee is scheduled for June 8, 2023, to discuss the biologics license application (BLA) for nirsevimab (Beyfortus®), a long-acting respiratory syncytial virus (RSV) F protein inhibitor, single dose monoclonal antibody (mAbs).
Read More
